Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes

Zheng, 2016, Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps, Oncotarget, 7, 59189, 10.18632/oncotarget.10830 Weiss, 2006, Kidney cancer: identification of novel targets for therapy, Kidney Int, 69, 224, 10.1038/sj.ki.5000065 Leibovich, 2003, Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials, Cancer, 97, 1663, 10.1002/cncr.11234 Atkins, 2018, Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma, Cancer Treat Rev, 70, 127, 10.1016/j.ctrv.2018.07.009 Choueiri, 2015, Cabozantinib versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1814, 10.1056/NEJMoa1510016 Choueiri, 2016, Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, Lancet Oncol, 17, 917, 10.1016/S1470-2045(16)30107-3 Choueiri, 2017, Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial, J Clin Oncol, 35, 591, 10.1200/JCO.2016.70.7398 Choueiri, 2018, Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update, Eur J Cancer, 94, 115, 10.1016/j.ejca.2018.02.012 2021 2017 Gomez de Liano, 2018, Cabozantinib in metastatic renal cell carcinoma (mRCC): real world experience from the UK, J Clin Oncol, 36, e16578, 10.1200/JCO.2018.36.15_suppl.e16578 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Ather, 2010, Impact of Charlson's comorbidity index on overall survival following tumor nephrectomy for renal cell carcinoma, Int Urol Nephrol, 42, 299, 10.1007/s11255-009-9636-8 Demircan, 2020, Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib, J Oncol Pharm Pract, 26, 1147, 10.1177/1078155219890032 Hollenbeak, 2019, Determinants of treatment in patients with stage IV renal cell carcinoma, BMC Urol, 19, 123, 10.1186/s12894-019-0559-0 Kang, 2020, The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma, J Cancer Res Clin Oncol, 146, 187, 10.1007/s00432-019-03042-7 Bodnar, 2019, Real-world experience of cabozantinib as second- or subsequent line treatment in patients with metastatic renal cell carcinoma: data from the Polish managed Access program, Clin Genitourin Cancer, 17, e556, 10.1016/j.clgc.2019.02.002 Bedke, 2020, Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma, Eur Urol, 79, 339, 10.1016/j.eururo.2020.12.005 Escudier, 2019, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, Ann Oncol, 30, 706, 10.1093/annonc/mdz056 Albiges, 2021, Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access Program, Eur J Cancer, 142, 102, 10.1016/j.ejca.2020.09.030 Stukalin, 2019, Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium, Curr Oncol, 26, e175, 10.3747/co.26.4595 Santoni, 2019, Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors, Cancers (Basel), 12, 84, 10.3390/cancers12010084 Prisciandaro, 2019, Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an Italian managed access program, Am J Clin Oncol, 42, 42, 10.1097/COC.0000000000000478 Procopio, 2018, Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program, Clin Genitourin Cancer, 16, e945, 10.1016/j.clgc.2018.03.014